EUVIMEDEUVIMED entdecken
FallberichtOpen Access

Successful Treatment of Carbapenem-Resistant Acinetobacter baumannii Meningitis With Sulbactam-Durlobactam

Pranita D Tamma iD, Shanan Immel, Sara M Karaba, Caitlin L Soto, Rick Conzemius, Emily Gisriel, Tsigereda Tekle, Haley Stambaugh, Emily Johnson, Jeffrey A Tornheim, Patricia J Simner

Clinical Infectious Diseases · 2024

DOI: 10.1093/cid/ciae210 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Pranita D Tamma und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Sulbactam, Acinetobacter Infections, Anti-Bacterial Agents. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The treatment of carbapenem-resistant Acinetobacter baumannii/calcoaceticus complex (CRAB) presents significant treatment challenges.

Methods

We report the case of a 42-year-old woman with CRAB meningitis who experienced persistently positive cerebrospinal fluid (CSF) cultures for 13 days despite treatment with high-dose ampicillin-sulbactam and cefiderocol. On day 13, she was transitioned to sulbactam-durlobactam and meropenem; 4 subsequent CSF cultures remained negative. After 14 days of sulbactam-durlobactam, she was cured of infection. Whole genome sequencing investigations identified putative mechanisms that contributed to the reduced cefiderocol susceptibility observed during cefiderocol therapy. Blood and CSF samples were collected pre-dose and 3-hours post initiation of a sulbactam-durlobactam infusion.

Results

The CRAB isolate belonged to sequence type 2. An acquired blaOXA-23 and an intrinsic blaOXA-51-like (ie, blaOXA-66) carbapenemase gene were identified. The paradoxical effect (ie, no growth at lower cefiderocol dilutions but growth at higher dilutions) was observed by broth microdilution after 8 days of cefiderocol exposure but not by disk diffusion. Potential markers of resistance to cefiderocol included mutations in the start codon of piuA and piuC iron transport genes and an A515V substitution in PBP3, the primary target of cefiderocol. Sulbactam and durlobactam were detected in CSF at both timepoints, indicating CSF penetration.

Conclusions

This case describes successful treatment of refractory CRAB meningitis with the administration of sulbactam-durlobactam and meropenem and highlights the need to be cognizant of the paradoxical effect that can be observed with broth microdilution testing of CRAB isolates with cefiderocol.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acinetobacter baumanniiSulbactamAcinetobacter InfectionsAnti-Bacterial AgentsCarbapenemsMeningitis, BacterialHumansFemaleAdultMicrobial Sensitivity TestsWhole Genome Sequencingbeta-LactamasesCephalosporinsBacterial ProteinsDrug CombinationsTreatment OutcomeDrug Resistance, Multiple, BacterialAzabicyclo Compounds

Stichwörter der Autor:innen

Acinetobacter baumanniiOXA-23antimicrobial resistancecefiderocolparadoxical effect

Substanzen

SulbactamAnti-Bacterial AgentsCarbapenemsdurlobactambeta-LactamasesCephalosporinsBacterial ProteinsDrug CombinationsAzabicyclo Compounds

Autor:innen und Institutionen

  • Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Department of Medicine, National Institutes of Health, Bethesda, Maryland, USA.
  • Department of Medicine, Johns Hopkins University of Medicine, Baltimore, Maryland, USA.
  • Department of Pharmacy, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Ares Genetics, Vienna, Austria.
  • Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

ORCID-Profile: Pranita D Tamma

Förderung

  • NIAID NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Tamma, P. D., Immel, S., Karaba, S. M., Soto, C. L., Conzemius, R., Gisriel, E., Tekle, T., Stambaugh, H., Johnson, E., Tornheim, J. A., & Simner, P. J. (2024). Successful Treatment of Carbapenem-Resistant Acinetobacter baumannii Meningitis With Sulbactam-Durlobactam. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae210

Vancouver

Tamma PD, Immel S, Karaba SM, Soto CL, Conzemius R, Gisriel E, et al. Successful Treatment of Carbapenem-Resistant Acinetobacter baumannii Meningitis With Sulbactam-Durlobactam. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciae210

BibTeX
@article{Tamma2024,
  author = {Tamma, Pranita D and Immel, Shanan and Karaba, Sara M and Soto, Caitlin L and Conzemius, Rick and Gisriel, Emily and Tekle, Tsigereda and Stambaugh, Haley and Johnson, Emily and Tornheim, Jeffrey A and Simner, Patricia J},
  title = {Successful Treatment of Carbapenem-Resistant Acinetobacter baumannii Meningitis With Sulbactam-Durlobactam},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  doi = {10.1093/cid/ciae210}
}
Kostenlos starten →